Beacon Therapeutics
laru-zova
Phase 3 VISTA topline data · H2 2026
← Back to reports
Whitepaper · MarketVIEW · ARVO 2026
ARVO 2026 just closed. Here's what it means for the RP market.
Gene Scope Intelligence · 12 May 2026
ARVO 2026 delivered the strongest retinitis pigmentosa gene therapy data we've seen. Four assets — three optogenetic, one gene replacement — moved the field meaningfully forward in a single five-day window, and re-cast the H2 2026 XLRP launch race as a three-horse contest with all three candidates now credible.
What follows is a working analyst's read of what mattered in the room and what it implies for the commercial opportunity through 2033: Beacon's laru-zova 12-month DAWN data, Nanoscope's MCO-010 3-year durability, Restore Vision's first-in-human RV-001 chimeric rhodopsin signal, and MeiraGTx's deep-discount re-acquisition of bota-vec from J&J.
01 · Beacon Therapeutics
laru-zova — Phase 2 DAWN delivers a clean dose-response in XLRP.
Twelve-month data from the Phase 2 DAWN trial of laru-zova (subretinal AAV) in X-linked RP. A clean dose response across both BCVA and low-luminance endpoints — the strongest XLRP gene replacement readout of the year so far, and the curtain-raiser for VISTA.
Beacon Therapeutics
laru-zova
Phase 2 DAWN · 12-month data · XLRP
Low-dose cohort
67%
gained ≥10 ETDRS letters (≥2-line BCVA improvement)
High-dose cohort
50%
gained ≥15 ETDRS letters (≥3-line BCVA improvement)
Also reported
- Sustained low-luminance visual acuity (LLVA) gains across both cohorts
- Improvements in mean macular sensitivity (microperimetry)
- Generally well-tolerated through 12 months — no new safety signals
Next catalyst
Phase 3 VISTA topline data · H2 2026
02 · Nanoscope Therapeutics
MCO-010 — three-year durability holds, and the rolling BLA is in.
RESTORE / REMAIN three-year readout of the gene-agnostic optogenetic MCO-010. The headline is durability — visual-acuity gain sustained from week 52 to week 152 with no second dose — and a safety profile clean enough that 14 of 15 patients are off inflammation treatment.
Nanoscope Therapeutics
MCO-010
RESTORE / REMAIN · 3-year data · mutation-agnostic RP
Durability · Week 152
~3 lines
ETDRS BCVA improvement sustained from week 52 to week 152
Vs. sham
5×
greater vision gains (BCVA-AUC)
Safety · Week 152
14/15
patients off inflammation treatment
Context
Untreated RP patients lose ~1.5 lines of vision every 5 years. MCO-010 patients gained ~3 lines and held them.
Regulatory status
Rolling BLA submission underway — potential first optogenetic approval in any indication
03 · Restore Vision
RV-001 — first-in-human signal for a new optogenetic modality.
Phase 1/2 168-day interim from Japan. A chimeric rhodopsin construct delivered by a single intravitreal AAV injection — and a meaningful clinical signal: patients with no light perception at baseline recovering light perception or better within a month.
Restore Vision
RV-001
Phase 1/2 · 168-day interim · advanced RP
Baseline
No light
perception · high-dose cohort start
Within 1 month
Light +
perception or better restored
Trial details
- Chimeric rhodopsin · single intravitreal AAV injection
- n=6 (3 low-dose, 3 high-dose) · Japan
- No DLTs · no drug-related SAEs through 168 days
Significance
First-in-human efficacy signal for a chimeric-rhodopsin optogenetic modality — a third mechanistic option alongside multi-characteristic and channelrhodopsin platforms.
04 · MeiraGTx · BD update
bota-vec — reclaimed from J&J at a deep discount, with a 2027 launch in sight.
Not new clinical data, but a BD story that re-shapes the XLRP race. After the Phase 3 LUMEOS primary endpoint miss in May 2025, J&J deprioritised the asset; MeiraGTx has bought it back at roughly 6% of the 2023 deal value, betting on the clinically meaningful LLVA secondary endpoints to clear regulators.
MeiraGTx / Johnson & Johnson
bota-vec
Asset re-acquisition · XLRP · April 2026
2023 · Sold to Janssen
Outbound deal
$415M
total transaction value, including $130M upfront
2026 · Re-acquired from J&J
Buyback
$25M
upfront + milestones + royalty — roughly 6% of the 2023 headline
What happened
- Phase 3 LUMEOS missed its primary endpoint (BCVA)
- Secondary endpoints showed clinically meaningful LLVA gains
- J&J deprioritised; MeiraGTx reclaimed at deep discount
Plan
Global regulatory filings · target 2027 launch
05 · The H2 2026 launch race
Three credible candidates. Two pivotal readouts. One year.
After ARVO 2026, the XLRP and broader RP gene therapy race compresses to a 12-month window. The three programmes below now all clear a credibility bar that didn't exist twelve months ago — and the order of arrival is not yet decided.
MeiraGTx
bota-vec
Global regulatory filings · target 2027 launch
Nanoscope Therapeutics
MCO-010
Rolling BLA submission completion · 2026
The bigger story
Patients waited decades. The data arrives in months.
For the first time in the history of the indication, retinitis pigmentosa patients have a realistic path to an approved disease-modifying therapy. H2 2026 will tell us whose — and whether it is one programme, two, or all three.
Disclaimer
This summary is produced for informational and business development purposes only. All data referenced are drawn from publicly disclosed ARVO 2026 presentations and company press releases as of 12 May 2026; figures are reported as disclosed by sponsors and may be subject to peer-reviewed publication adjustment. Forward-looking commentary represents Gene Scope Intelligence's independent analytical judgement and does not constitute investment advice or a solicitation to invest. Gene Scope Intelligence has no affiliation with any of the named companies. Third-party trademarks, asset names and trial identifiers belong to their respective owners.
Gene Scope Intelligence is a trading brand of Assay Advantage Ltd (UK Company No. 5807728), publisher of Gene Scope Intelligence and sister brand to VacZine Analytics. © 2026 Assay Advantage Ltd. All rights reserved.